Skip to content
OpenCapital
Get started

Ginkgo Bioworks DNA Increase (decrease) in contract liabilities and current deferred income

Increase (decrease) in contract liabilities and current deferred income at other companies

Charles River Laboratories logo
Charles River LaboratoriesCRL
$5.2M+528%

Other financials

Income statement

See full
Revenue$19.5M-49.1%
Gross profit$16.4M-52.0%
Operating income-$71.4M+11.9%
Net income-$82.6M+9.2%
EPS (diluted)-$1.42+27.6%

Balance sheet

See full
Cash & equivalents$188.7M-46.9%
Total debt$410.7M-5.5%
Total equity$443.2M-31.6%
Total assets$1.0B-20.1%

Cash flow

See full
Operating cash flow-$46.7M+9.4%
CapEx$1.9M-74.6%
Free cash flow-$48.6M+17.8%

Valuation

See full
Market cap$625.16M+24.6%
Enterprise value$847.19M+45.9%
P/S4.4×+2.2×

Profitability

See full
Operating margin-210.7%+7.6pp
Net margin-215.4%+8.3pp
FCF margin-119%-21.2pp

Returns & leverage

See full
Return on equity-55.8%-1.8pp
Debt / equity0.9×+0.3×
Current ratio5.2×+0.3×

Where this comes from

Reported directly by Ginkgo Bioworks in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ginkgo Bioworks's increase (decrease) in contract liabilities and current deferred income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ginkgo Bioworks's increase (decrease) in contract liabilities and current deferred income?
Ginkgo Bioworks (DNA) reported increase (decrease) in contract liabilities and current deferred income of -$2.61M in Q1 2026.
How has Ginkgo Bioworks's increase (decrease) in contract liabilities and current deferred income changed year-over-year?
Ginkgo Bioworks's increase (decrease) in contract liabilities and current deferred income increased by 80.2% year-over-year, from -$13.19M to -$2.61M.
What is the long-term trend for Ginkgo Bioworks's increase (decrease) in contract liabilities and current deferred income?
Over 4 years (2021 to 2025), Ginkgo Bioworks's increase (decrease) in contract liabilities and current deferred income has grown at a 30.9% compound annual growth rate (CAGR), from -$11.03M to -$32.39M.